sunny.png
Thursday December 5th, 2019 6:05PM

Company says it will seek approval of Alzheimer's drug

By The Associated Press
Related Articles
  Contact Editor

The drug company Biogen Inc. said Tuesday it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia.

The announcement was a surprise because the company earlier this year stopped two studies of the drug when partial results suggested it was not likely to be successful. The company now says a new analysis of more results suggest that the drug helped reduce a decline of thinking skills at the highest dose.

The drug, called aducanumab, aims to help the body clear harmful plaques from the brain. Cambridge, Massachusetts-based Biogen is developing it with a Japanese company, Eisai Co. Ltd.

More than 5 million people in the United States and millions more worldwide have Alzheimer's. Current drugs only temporarily ease symptoms and do not slow the loss of memory and thinking skills. Dozens of efforts to develop a drug to slow or reverse the course of the disease have failed.

The two studies tested aducanumab, given as monthly infusions, in more than 3,000 patients with mild cognitive impairment or early dementia due to Alzheimer's. The company said Tuesday that in one study, those given a high dose showed 23% less decline on one measure of thinking skills and smaller declines on other measures.

However, no details were given on how much that decline meant in absolute terms. For example, the company didn't say how much difference it made in practical matters, like whether patients were able to dress or feed themselves or live independently longer, just that these skills overall declined less for those on the high dose of the drug.

"It's a tricky question" whether the results are truly meaningful for patients until more details are known, said Dr. Ronald Petersen, a Mayo Clinic dementia specialist who has consulted for Biogen on the studies.

But filing for federal Food and Drug Administration approval "gives some hopes for patients and families that there may be disease-modifying therapies out there," he said.

The company said more details would be given at a conference in December, including on safety. The company said the most common side effects were inflammation in the brain, most of which did not cause symptoms or lasting problems, and headaches. The brain inflammation has been seen in other studies of Alzheimer's medicines that target the brain plaques.

"We're really encouraged by the information that they've provided today," the largest benefit so far for any experimental medicine, said Rebecca Edelmayer, a scientist at the Alzheimer's Association, which had no role in the studies.

Biogen said it would offer aducanumab now to patients enrolled in these and earlier studies of it.

Biogen shares were up more than 26% to $285.79 Tuesday morning, but some on Wall Street remained skeptical.

Mizuho Securities USA analyst Salim Syed said he wants to know more about the FDA's involvement in Biogen's decision. He also said in a research note that it's still just a hypothesis that removing beta amyloid plaques can benefit Alzheimer's patients.

The company's announcement "does not guarantee approval and questions remain," he said.

___

AP Health Writer Tom Murphy in Indianapolis contributed reporting.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content.

  • Associated Categories: Associated Press (AP), AP Health, AP Business, AP Business - Corporate News, AP Health - Senior Health
© Copyright 2019 AccessWDUN.com
All rights reserved. This material may not be published, broadcast, rewritten, or redistributed without permission.
US diplomat drawn into Trump's Ukraine effort set to testify
The top US diplomat in Ukraine, William Taylor, who was drawn into a Trump administration effort to leverage US military aid for Ukraine, is set to testify to Congress
9:09AM ( 16 minutes ago )
Bolivia says Morales near outright victory, unrest spreads
Rioting have broken out in parts of Bolivia among opponents of President Evo Morales after electoral authorities said that a resumed vote count after a day-long delay put the leader close to avoiding a risky runoff in his bid for a fourth term
9:05AM ( 21 minutes ago )
UK's Johnson prepares push to heave Brexit bill over line
British lawmakers from across the political spectrum are plotting to put the brakes on Prime Minister Boris Johnson's drive to push his European Union divorce bill through the House of Commons in just three days
9:02AM ( 24 minutes ago )
Associated Press (AP)
$260 million deal averts 1st federal trial on opioid crisis
The nation's three largest drug distributors and a drugmaker have reached a $260 million deal to settle a lawsuit related to the toll of opioids, averting the first federal trial on the crisis
5:22PM ( 16 hours ago )
Clusters of illness linked to CBD vapes share 2nd connection
A pioneer in marketing CBD as a health product has pleaded guilty to selling large quantities of synthetic marijuana which was secretly added to vapes, sickening dozens.
4:09PM ( 17 hours ago )
Study raises fresh dementia concerns from playing pro soccer
A study of former professional soccer players in Scotland finds they were less likely to die of common causes such as heart disease and cancer compared to the general population but were more likely to die from dementia
12:53PM ( 20 hours ago )
AP Health
McDonald's comparable-store sales feed on deliveries
McDonald's delivery boosts same-store sales, but at a cost
8:53AM ( 33 minutes ago )
World shares rise after upbeat talk on China-US trade
World shares gain following upbeat talk on China-US trade dispute
7:54AM ( 1 hour ago )
Under Armour founder Kevin Plank relinquishes CEO post
Under Armour founder Plank will step down from the CEO role
7:54AM ( 1 hour ago )
AP Business
Trump cites his support for Medicare, slams Medicare for All
Trump accuses Democrats of an all-out attempt to “totally obliterate Medicare” and portrays himself as the program’s defender
4:27PM ( 2 weeks ago )
Trump touts support for Medicare, slams ‘Medicare for All’
Trump travels to Florida to tout support for Medicare, slam Democrats on their ‘Medicare for All’ plan
11:16AM ( 2 weeks ago )
Japan ups sales tax to 10% amid signs economy is weakening
Japan raises consumption tax to 10%, raising worries economy might sputter
4:14AM ( 3 weeks ago )
AP Health - Senior Health
US diplomat drawn into Trump's Ukraine effort set to testify
The top US diplomat in Ukraine, William Taylor, who was drawn into a Trump administration effort to leverage US military aid for Ukraine, is set to testify to Congress
9:09AM ( 16 minutes ago )
Bolivia says Morales near outright victory, unrest spreads
Rioting have broken out in parts of Bolivia among opponents of President Evo Morales after electoral authorities said that a resumed vote count after a day-long delay put the leader close to avoiding a risky runoff in his bid for a fourth term
9:05AM ( 21 minutes ago )
UK's Johnson prepares push to heave Brexit bill over line
British lawmakers from across the political spectrum are plotting to put the brakes on Prime Minister Boris Johnson's drive to push his European Union divorce bill through the House of Commons in just three days
9:02AM ( 24 minutes ago )
Russia, Turkey leaders hold talks on fate of Syria border
The presidents of Turkey and Russia are meeting in the Black Sea resort town of Sochi Tuesday, hours before a five-day cease-fire in northern Syria between Turkish troops and Syrian Kurdish fighters is set to expire
9:01AM ( 24 minutes ago )
More choices and stable premiums for 'Obamacare' next year
More choices and stable premiums for 'Obamacare' next year, but court case looms over the program
9:00AM ( 25 minutes ago )